HK1216142A1 - 生產免疫偶聯物的方法 - Google Patents

生產免疫偶聯物的方法

Info

Publication number
HK1216142A1
HK1216142A1 HK16104008.4A HK16104008A HK1216142A1 HK 1216142 A1 HK1216142 A1 HK 1216142A1 HK 16104008 A HK16104008 A HK 16104008A HK 1216142 A1 HK1216142 A1 HK 1216142A1
Authority
HK
Hong Kong
Prior art keywords
methods
producing immunoconjugates
immunoconjugates
producing
Prior art date
Application number
HK16104008.4A
Other languages
English (en)
Inventor
Alan Hunter
Thomas Linke
Tim Pabst
Michaela Wendeler
Xiangyang Wang
Chris Tohmpson
Guoling Xi
Andrew Fulton
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of HK1216142A1 publication Critical patent/HK1216142A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1136—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by reversible modification of the secondary, tertiary or quarternary structure, e.g. using denaturating or stabilising agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK16104008.4A 2012-12-20 2016-04-08 生產免疫偶聯物的方法 HK1216142A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261740111P 2012-12-20 2012-12-20
PCT/US2013/076625 WO2014100443A2 (en) 2012-12-20 2013-12-19 Methods of producing immunoconjugates

Publications (1)

Publication Number Publication Date
HK1216142A1 true HK1216142A1 (zh) 2016-10-21

Family

ID=50979399

Family Applications (2)

Application Number Title Priority Date Filing Date
HK16103571.3A HK1215547A1 (zh) 2012-12-20 2016-03-29 生產免疫偶聯物的方法
HK16104008.4A HK1216142A1 (zh) 2012-12-20 2016-04-08 生產免疫偶聯物的方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK16103571.3A HK1215547A1 (zh) 2012-12-20 2016-03-29 生產免疫偶聯物的方法

Country Status (10)

Country Link
US (1) US9920124B2 (zh)
EP (2) EP3494992B1 (zh)
JP (1) JP6553515B2 (zh)
CN (2) CN110950955A (zh)
AU (2) AU2013361235B2 (zh)
CA (1) CA2894908C (zh)
DK (1) DK2934597T3 (zh)
ES (2) ES2710314T3 (zh)
HK (2) HK1215547A1 (zh)
WO (1) WO2014100443A2 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3334747B1 (en) * 2015-08-13 2023-09-27 Amgen Inc. Charged depth filtration of antigen-binding proteins
WO2022068141A1 (zh) * 2020-09-29 2022-04-07 昆明赛诺制药股份有限公司 人源化抗-cd22重组免疫毒素及其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3060165A (en) 1962-10-23 Preparation of toxic ricin
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5079163A (en) 1985-03-29 1992-01-07 Cetus Corporation Recombinant ricin toxin fragments
US4689401A (en) 1986-03-06 1987-08-25 Cetus Corporation Method of recovering microbially produced recombinant ricin toxin a chain
US4892827A (en) 1986-09-24 1990-01-09 The United States Of America As Represented By The Department Of Health And Human Services Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects
ATE182175T1 (de) 1990-05-11 1999-07-15 Us Health Verbesserte exotoxine aus pseudomonas mit geringer toxität bei tieren und hoher zelltötender aktivität
US5608039A (en) 1990-10-12 1997-03-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Single chain B3 antibody fusion proteins and their uses
AU675440B2 (en) 1992-06-18 1997-02-06 United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Recombinant (pseudomonas) exotoxin with increased activity
CA2284665C (en) * 1997-03-20 2010-08-17 David Fitzgerald Recombinant antibodies and immunoconjugates targeted to cd-22 bearing cells and tumors
US6296843B1 (en) 1998-04-03 2001-10-02 The Penn State Research Foundation Mutagenized IL 13-based chimeric molecules
US7355012B2 (en) 2001-09-26 2008-04-08 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Mutated anti-CD22 antibodies with increased affinity to CD22-expressing leukemia cells
CN104645327A (zh) * 2003-07-24 2015-05-27 依奈特制药公司 使用nk细胞增效化合物提高治疗性抗体功效的方法和组合物
WO2005012495A2 (en) * 2003-08-01 2005-02-10 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, National Institutes Of Health Methods for expression and purification of immunotoxins
US7982011B2 (en) 2003-11-25 2011-07-19 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Mutated anti-cd22 antibodies and immunoconjugates
CN1676531A (zh) * 2004-04-02 2005-10-05 北京安波特基因工程技术有限公司 一种含（Arg) 9肽段的基于假单胞菌外毒素的重组免疫毒素
ATE524489T1 (de) 2005-07-29 2011-09-15 Us Gov Health & Human Serv Mutierte pseudomonas-exotoxine mit reduzierter antigenität
EP1845103B1 (en) * 2006-04-10 2015-02-25 Boehringer Ingelheim RCV GmbH & Co KG Method for refolding a protein
ZA200809776B (en) * 2006-05-30 2010-03-31 Genentech Inc Antibodies and immunoconjugates and uses therefor
TWI476207B (zh) * 2006-07-14 2015-03-11 Genentech Inc 重組蛋白之再摺疊
ES2642516T3 (es) 2007-09-04 2017-11-16 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Supresiones en el dominio II de la exotoxina A de Pseudomonas que reducen la toxicidad no específica
EP2475398B1 (en) * 2009-09-11 2015-05-20 The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services Improved pseudomonas exotoxin a with reduced immunogenicity
EP3797847A1 (en) * 2010-07-30 2021-03-31 Medlmmune, LLC Purified active polypeptides or immunoconjugates
EP2451238B1 (en) 2010-11-05 2015-01-07 Alcatel Lucent Control message encoding
WO2012152912A1 (en) 2011-05-12 2012-11-15 Newvectys Genetically modified pig as a cancer prone model

Also Published As

Publication number Publication date
ES2929876T3 (es) 2022-12-02
EP2934597B1 (en) 2018-10-17
CA2894908A1 (en) 2014-06-26
ES2710314T3 (es) 2019-04-24
WO2014100443A2 (en) 2014-06-26
EP2934597A2 (en) 2015-10-28
AU2013361235A1 (en) 2015-07-02
EP2934597A4 (en) 2016-07-20
JP6553515B2 (ja) 2019-07-31
CN110950955A (zh) 2020-04-03
WO2014100443A3 (en) 2015-07-16
CN105007937B (zh) 2019-11-19
EP3494992B1 (en) 2022-07-27
CN105007937A (zh) 2015-10-28
AU2013361235B2 (en) 2018-07-26
JP2016503062A (ja) 2016-02-01
US9920124B2 (en) 2018-03-20
CA2894908C (en) 2022-07-12
EP3494992A1 (en) 2019-06-12
HK1215547A1 (zh) 2016-09-02
AU2018232979A1 (en) 2018-10-11
DK2934597T3 (en) 2019-02-11
US20150337040A1 (en) 2015-11-26

Similar Documents

Publication Publication Date Title
HUE037048T2 (hu) Eljárások 4-cikloalkiloxibenzolszulfonamidok elõállítására
HK1212388A1 (zh) 組織產生方法
HK1212261A1 (zh) 組織生成的方法
EP2836221A4 (en) METHOD OF USING CYCLODEXTRIN
ZA201406494B (en) Methods of producing sulfilimine compounds
LT2833884T (lt) Ccr3-inhibitorių panaudojimas
PL2836460T3 (pl) Sposób wytwarzania grafenu
PL2931937T3 (pl) Sposób wytwarzania układów nanocząstek metali
GB201222832D0 (en) Manufacture of hollow parts
IL236312A0 (en) Preparation of 18f-flucyclobin
GB201220155D0 (en) Method of manufacture
IL237862A0 (en) Methods to reduce the formation of scale
HK1203967A1 (zh) 神經節苷脂生產的方法
HK1210225A1 (zh) 生產台勾霉素 的流程
ZA201500488B (en) Manufacture of wheels
EP2892529A4 (en) USES OF (-) - PERHEXILINE
HK1216142A1 (zh) 生產免疫偶聯物的方法
EP2887938A4 (en) PROCESS FOR PREPARING TECOVIRIMAT
IL234080A0 (en) Tetrazolylhydroxyimino derivatives and methods for their production
GB201215942D0 (en) Method of treatent
EP2812301A4 (en) PROCESS FOR PREPARING ALCOHOLS
GB201222952D0 (en) Treatent of cancer
GB201221118D0 (en) Methods of treatment
GB201216740D0 (en) Methods of treatment
GB201216748D0 (en) Methods of treatment

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20231219